Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies

British Journal of Haematology

Volumn 138, Issue 2, 2007, Pages 146-152

  Levenga, Tjakiena Henriette ^a   Timmer Bonte, Johanna N H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Febrile neutropenia; Granulocyte colony stimulating factor; Haematological malignancy; Prophylaxis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG POTENCY; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ADULT; COLONY-STIMULATING FACTORS; COST-BENEFIT ANALYSIS; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION;

EID: 34250818884     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06653.x     Document Type: Review

References (55)

1. Bennett, C.L., Stinson, T.J., Tallman, M.S., Stadtmauer, E.A., Marsh, R.W., Friedenberg, W., Lazarus, H.M., Kaminer, L., Golub, R.M. Rowe, J.M. (1999) Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Annals of Oncology, 10, 177 182.
2. Bennett, C.L., Hynes, D., Godwin, J., Stinson, T.J., Golub, R.M. Appelbaum, F.R. (2001) Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Investigation, 19, 603 610.
3. Blijlevens, N.M., Donnelly, J.P. de Pauw, B.E. (2005) Microbiologic consequences of new approaches to managing hematologic malignancies. Reviews in Clinical and Experimental Hematology, 9, E2.
4. Bodey, G.P., Buckley, M., Sathe, Y.S. Freireich, E.J. (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine, 64, 328 340.
5. Bohlius, J., Reiser, M., Schwarzer, G. Engert, A. (2004) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews, CD003189.
6. Bradstock, K., Matthews, J., Young, G., Lowenthal, R., Baxter, H., Arthur, C., Bashford, J., Brighton, T., Cannell, P., Dunlop, L., Durrant, S., Enno, A., Eliadis, P., Gill, D., Gillett, A., Gottlieb, D., Januszewicz, H., Joshua, D., Leahy, M., Schwarer, A. Taylor, K. (2001) Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia, 15, 1331 1338.
7. Calhoun, E.A., Schumock, G.T., McKoy, J.M., Pickard, S., Fitzner, K.A., Heckinger, E.A., Powell, E.F., McCaffrey, K.R. Bennett, C.L. (2005) Granulocyte colony - stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. Pharmacoeconomics, 23, 767 775.
8. Casadevall, N., Durieux, P., Dubois, S., Hemery, F., Lepage, E., Quarre, M.C., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Chomienne, C., Ribrag, V., Stamatoullas, A., Marie, J.P., Vekhoff, A., Maloisel, F., Navarro, R., Dreyfus, F. Fenaux, P. (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood, 104, 321 327.
9. Cosler, L.E., Calhoun, E.A., Agboola, O. Lyman, G.H. (2004) Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy, 24, 488 494.
10. Dekker, A., Bulley, S., Beyene, J., Dupuis, L.L., Doyle, J.J. Sung, L. (2006) Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. Journal of Clinical Oncology, 24, 5207 5215.
11. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G. Tilly, H. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. New England Journal of Medicine, 332, 1678 1683.
12. Doorduijn, J.K., Buijt, I.H.B., van der Holt, B., van Agthoven, M., Sonneveld, P. Uyl-de Groot, C.A. (2004) Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica, 89, 1109 1117.
13. Estey, E. (1998) Hematopoietic growth factors in the treatment of acute leukemia. Current Opinion in Oncology, 10, 23 30.
14. Geissler, K., Koller, E., Hubmann, E., Niederwieser, D., Hinterberger, W., Geissler, D., Kyrle, P., Knobl, P., Pabinger, I., Thalhammer, R., Schwarzinger, I., Mannhalter, C., Jaeger, U., Heinz, R., Linkesch, W. Lechner, K. (1997) Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - a randomized phase-III study. Blood, 90, 590 596.
15. Godwin, J.E., Kopecky, K.J., Head, D.R., Willman, C.L., Leith, C.P., Hynes, H.E., Balcerzak, S.P. Appelbaum, F.R. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood, 91, 3607 3615.
16. Goldstone, A.H., Burnett, A.K., Wheatley, K., Smith, A.G., Hutchinson, R.M. Clark, R.E. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1302 1311.
17. Green, M.D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R.I., Samonigg, H., Clemens, M.R., Zani, V., Liang, B.C., Renwick, J. Piccart, M.J. (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology, 14, 29 35.
18. Grigg, A., Solal-Celigny, P., Hoskin, P., Taylor, K., McMillan, A., Forstpointner, R., Bacon, P., Renwick, J. Hiddemann, W. (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leukemia & Lymphoma, 44, 1503 1508.
19. Hackshaw, A., Sweetenham, J. Knight, A. (2004) Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? British Journal of Cancer, 90, 1302 1305.
20. Harousseau, J.L. Wu, D. (1995) The use of GM-CSF and G-CSF in the treatment of acute leukemias. Leukemia & Lymphoma, 18, 405 412.
21. Harousseau, J.L., Witz, B., Lioure, B., Hunault-Berger, M., Desablens, B., Delain, M., Guilhot, F., Le Prise, P.Y., Abgrall, J.F., Deconinck, E., Guyotat, D., Vilque, J.P., Casassus, P., Tournilhac, O., Audhuy, B. Solary, E. (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. Journal of Clinical Oncology, 18, 780 787.
22. Heil, G., Hoelzer, D., Sanz, A., Lechner, K., Noens, L., Szer, J., Ganser, A., Matcham, J. Renwick, J. (2006) Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia, 20, 404 409.
23. Heil, G., Hoelzer, D., Sanz, M.A., Lechner, K., Liu Yin, J.A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J. Barge, A. (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood, 90, 4710 4718.
24. Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. Ost, A. (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92, 68 75.
25. Ho, V.T., Mirza, N.Q., Junco, D.D., Okamura, T. Przepiorka, D. (2003) The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplantation, 32, 771 775.
26. Holmes, F.A., O'Shaughnessy, J.A., Vukelja, S., Jones, S.E., Shogan, J., Savin, M., Glaspy, J., Moore, M., Meza, L., Wiznitzer, I., Neumann, T.A., Hill, L.R. Liang, B.C. (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Journal of Clinical Oncology, 20, 727 731.
27. Jadersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A. Hellstrom-Lindberg, E. (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106, 803 811.
28. Khoury, H.J., Loberiza, Jr., F.R., Ringden, O., Barrett, A.J., Bolwell, B.J., Cahn, J.Y., Champlin, R.E., Gale, R.P., Hale, G.A., Urbano-Ispizua, A., Martino, R., McCarthy, P.L., Tiberghien, P., Verdonck, L.F. Horowitz, M.M. (2006) Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood, 107, 1712 1716.
29. Klumpp, T.R., Mangan, K.F., Goldberg, S.L., Pearlman, E.S. Macdonald, J.S. (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. Journal of Clinical Oncology, 13, 1323 1327.
30. Larson, R.A., Dodge, R.K., Linker, C.A., Stone, R.M., Powell, B.L., Lee, E.J., Schulman, P., Davey, F.R., Frankel, S.R., Bloomfield, C.D., George, S.L. Schiffer, C.A. (1998) A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood, 92, 1556 1564.
31. Lowenberg, B., van Putten, W., Theobald, M., Gmur, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., Kovacsovics, T., Gratwohl, A., Daenen, S., Huijgens, P. Boogaerts, M. (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. New England Journal of Medicine, 349, 743 752.
32. Lyman, G.H. Kuderer, N.M. (2004) The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Critical Reviews in Oncology/hematology, 50, 129 146.
33. Lyman, G.H., Kuderer, N., Greene, J. Balducci, L. (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. European Journal of Cancer, 34, 1857 1864.
34. Mantovani, L., Lentini, G., Hentschel, B., Wickramanayake, P.D., Loeffler, M., Diehl, V. Tesch, H. (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. British Journal of Haematology, 109, 367 375.
35. McQuaker, I.G., Hunter, A.E., Pacey, S., Haynes, A.P., Iqbal, A. Russell, N.H. (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. Journal of Clinical Oncology, 15, 451 457.
36. Messori, A., Trippoli, S. Tendi, E. (1996) G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. Journal of Clinical Pharmacy and therapeutics, 21, 57 63.
37. Negrin, R.S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S. Greenberg, P.L. (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82, 737 743.
38. Negrin, R.S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S. Greenberg, P.L. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood, 87, 4076 4081.
39. Ohno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T., Ueda, T., Minami, S., Morishima, Y. Saito, Y. (1994) A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood, 83, 2086 2092.
40. Ottmann, O.G., Hoelzer, D., Gracien, E., Ganser, A., Kelly, K., Reutzel, R., Lipp, T., Busch, F.W., Schwonzen, M. Heil, G. (1995) Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood, 86, 444 450.
41. Ravandi, F. (2006) Role of cytokines in the treatment of acute leukemias: a review. Leukemia, 20, 563 571.
42. Ringden, O., Labopin, M., Gorin, N.C., Le Blanc, K., Rocha, V., Gluckman, E., Reiffers, J., Arcese, W., Vossen, J.M., Jouet, J.P., Cordonnier, C. Frassoni, F. (2004) Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 22, 416 423.
43. Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer, E.A. Wiernik, P.H. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 86, 457 462.
44. Smith, D.H., Adams, J.R., Johnston, S.R., Gordon, A., Drummond, M.F. Bennett, C.L. (2002) A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Annals of Oncology, 13, 1590 1597.
45. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Bennett, C.L., Cantor, S.B., Crawford, J., Cross, S.J., Demetri, G., Desch, C.E., Pizzo, P.A., Schiffer, C.A., Schwartzberg, L., Somerfield, M.R., Somlo, G., Wade, J.C., Wade, J.L., Winn, R.J., Wozniak, A.J. Wolff, A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 3187 3205.
46. Spielberger, R., Stiff, P., Bensinger, W., Gentile, T., Weisdorf, D., Kewalramani, T., Shea, T., Yanovich, S., Hansen, K., Noga, S., McCarty, J., LeMaistre, C.F., Sung, E.C., Blazar, B.R., Elhardt, D., Chen, M.G. Emmanouilides, C. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. New England Journal of Medicine, 351, 2590 2598.
47. Stinson, T.J., Adams, J.R., Bishop, M.R., Kruse, S., Tarantolo, S. Bennet, C.L. (2000) Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplantation, 26, 663 666.
48. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L. Schiffer, C.A. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. New England Journal of Medicine, 332, 1671 1677.
49. Thomas, X., Raffoux, E., Botton, S., Pautas, C., Arnaud, P., de Revel, T., Reman, O., Terre, C., Corront, B., Gardin, C., Le, Q.H., Quesnel, B., Cordonnier, C., Bourhis, J.H., Elhamri, M., Fenaux, P., Preudhomme, C., Michallet, M., Castaigne, S. Dombret, H. (2007) Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia, 21, 453 461.
50. Timmer-Bonte, J.N.H. Tjan-Heijnen, V.C.G. (2006) Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Anti-cancer Drugs, 17, 881 889.
51. Timmer-Bonte, J.N., Adang, E.M., Smit, H.J., Biesma, B., Wilschut, F.A., Bootsma, G.P., de Boo, T.M. Tjan-Heijnen, V.C. (2006) Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. Journal of Clinical Oncology, 24, 2991 2997.
52. Usuki, K., Urabe, A., Masaoka, T., Ohno, R., Mizoguchi, H., Hamajima, N., Miyazaki, T., Niitsu, Y., Yoshida, Y., Miura, A., Shibata, A., Abe, T., Miura, Y., Ikeda, Y., Nomura, T., Nagao, T., Saitou, H., Shirakawa, S., Ohkuma, M., Matsuda, T., Nakamura, T., Horiuchi, A., Kuramoto, A., Kimura, I., Irino, S., Niho, Y., Takatsuki, K., Tomonaga, M., Uchino, H. Takaku, F. (2002) Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. British Journal of Haematology, 116, 103 112.
53. Vose, J.M., Crump, M., Lazarus, H., Emmanouilides, C., Schenkein, D., Moore, J., Frankel, S., Flinn, I., Lovelace, W., Hackett, J. Liang, B.C. (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. Journal of Clinical Oncology, 21, 514 519.
54. Witz, F., Sadoun, A., Perrin, M.C., Berthou, C., Briere, J., Cahn, J.Y., Lioure, B., Witz, B., Francois, S., Desablens, B., Pignon, B., Le Prise, P.Y., Audhuy, B., Caillot, D., Casassus, P., Delain, M., Christian, B., Tellier, Z., Polin, V., Hurteloup, P. Harousseau, J.L. (1998) A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood, 91, 2722 2730.
55. Zittoun, R., Suciu, S., Mandelli, F.W.T., de Witte, T., Thaler, J., Stryckmans, P., Hayat, M., Peetermans, M., Cadiou, M., Solbu, G., Petti, M.C. Willemze, R. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Journal of Clinical Oncology, 14, 2150 2159.